Intuitive Surgical Q3 2026 Earnings: $3.05B of Revenue, a $450M Settlement, and a 7% Selloff

Intuitive Surgical grew revenue 22% to $3.05 billion, beat on both the top line and adjusted earnings, placed a record 546 da Vinci systems — and reported GAAP net income down 26% to $523 million, because a $450 million antitrust settlement landed in a single expense line. The market's verdict was swift: shares fell about 7% after hours. This is the razor-and-blades quarter where the blades sold beautifully and the lawyers took the profit.

The Headline Numbers​

Every figure below comes from the Q3 2026 earnings release (Exhibit 99.1 to the October 20, 2026 Form 8-K; no Q3 10-Q had been filed) and the FY2024–FY2025 Forms 10-K.

Read the table top to bottom and the quarter splits in two. Everything above operating income is acceleration: revenue up nearly 22%, gross profit up more than 25%. Everything below it is the settlement: GAAP operating income down 22%, GAAP net income down 26%. Add back the disclosed $347 million net-of-tax settlement impact and net income would have been roughly $870 million — up about 23% instead of down 26%. The release also discloses a $22 million net-of-tax IEEPA tariff-refund benefit ($0.06 per share), so the fully cleaned number is closer to $848 million. Either way, the operating business grew in the low twenties; a litigation line decided the GAAP print.

Revenue Deep Dive​

All three revenue streams grew double digits, but the mix is the thesis — this company sells the razor cheap-ish and the blades forever:

Instruments and accessories — 59 cents of every revenue dollar — grew 18% on procedure volume: da Vinci procedures up approximately 14%, Ion procedures up approximately 31%, for 15% combined growth. The release attributes the increase "primarily" to that procedure growth, which is the flywheel working as designed: every installed system generates a stream of single-use instruments at $900 to $3,700 of revenue per procedure (per the 10-K), and customers performed, on average, over 10,000 procedures per day during the quarter.

Systems revenue was the upside surprise at +30%, "reflecting increased da Vinci system placements and a higher lease installed base." The company placed 546 da Vinci systems against 427 a year ago, of which 315 were da Vinci 5 systems (versus 240) — the next-generation platform is now 58% of placements. More than half of placements (291 of 546) went out under operating leases, 160 of them usage-based, which trades upfront revenue for a recurring stream and makes the +30% print all the more striking.

Services grew 22%, tracking the installed base: 12,094 da Vinci systems (+12% year over year) and 1,152 Ion systems (+21%). CEO Dave Rosa's summary in the release: "Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms." Notably absent is any claim that demand exceeds supply or that the demand environment strengthened — the release's demand language is descriptive (procedure counts, placements, installed base), not superlative. For a company growing revenue 22%, management is letting the numbers talk.

The Margin Story​

Gross margin expanded two full points year over year, to 68.4% from 66.4%, even with tariffs biting. That deserves emphasis: the 2026 outlook bakes in an estimated 0.9% of revenue in tariff drag on non-GAAP gross margin (Intuitive manufactures most instruments in Mexico and most endoscopes in Germany), and the quarter still expanded. Part of the expansion is the $27.8 million IEEPA refund benefit sitting inside cost of revenue — about 0.9 points of margin — but the rest is mix and scale.

Operating margin tells the settlement story in one row: 19.4% reported, 34.2% without the $450 million charge — which would be the best operating margin of the three quarters shown. Strip all $454.9 million of litigation charges out of SG&A and the underlying SG&A ratio is 20.6% of revenue, improved from 22.9% a year ago. R&D held steady at 13.4% of revenue versus 13.2%. There is no cost-control problem here; there is a one-line legal event.

On pricing, the release says nothing at all — no "pricing momentum," no increases passed through. That silence is worth noting against the 10-K's risk factor: Chinese provinces have capped what hospitals can charge for robotic surgery, pressuring instrument pricing there. So far "not material," but it is the one margin threat the numbers cannot yet show.

The One Big Question: Is This a $523M Quarter or a $1.05B Quarter?​

GAAP says $522.8 million of attributable net income. Non-GAAP says $1,054.5 million — more than double. The release's own reconciliation bridges them:

Two adjustments do nearly all the work: the $454.9 million of litigation charges (one-time, or at least non-recurring in size) and $212.6 million of share-based compensation (emphatically recurring — the release itself warns SBC "has been, and will continue to be for the foreseeable future, a significant recurring expense"). That split is the honest answer to the question. The settlement should be added back to judge the quarter; the SBC should not, because it is real dilution happening every quarter.

Do both adjustments and the two routes converge neatly: GAAP ex-settlement-ex-refund is about $848 million, and non-GAAP ex-SBC is about $842 million. Call it $845 million of true operating earnings — up roughly 20% year over year, in line with revenue. Neither $523 million nor $1.05 billion is the number to carry forward.

What Wall Street Thinks​

By the numbers it was a beat: revenue of $3.05 billion against roughly $2.91 billion of consensus, adjusted EPS of $3.00 against roughly $2.60–$2.65. But shares fell about 7% after hours and into the next session, with coverage pointing at two culprits beyond the settlement itself: a narrowed 2026 procedure-growth outlook — worldwide da Vinci procedure growth of approximately 14% to 15%, with the company expecting "to be closer to the midpoint" — and a valuation that, into the print, required upside surprises to hold. Ahead of earnings, UBS had reiterated a Buy with a $500 target, arguing procedure-volume concerns were overdone. The quarter's 15% procedure growth validated that; the market sold it anyway.

Tracking a $3B Quarter in Plain Text​

Double-entry forces every dollar to reconcile, which is exactly what a quarter split between a 22% revenue beat and a 26% earnings decline needs. Read the how we model every company guide for the conventions; here is the quarter's income statement as booked, with the two one-offs isolated as second postings that sum with the first to the filed lines (income negative, expenses positive, by Beancount sign convention):

; FY2026Q3 Income Statement — three months ended September 30, 2026
; Check: −3,048.7 + 992.2 + (−27.8) + 628.5 + 454.9 + 408.3 + (−75.8) + 144.0 + 1.6 + 522.8 = 0 ✓
 
2026-09-30 * "Intuitive Surgical, Inc." "FY2026Q3 Income Statement"
  Income:Revenue                              -3048.7 MUSD
  Expenses:CostOfRevenue                         992.2 MUSD
  Expenses:CostOfRevenue                         -27.8 MUSD
  Expenses:SellingGeneralAdministrative           628.5 MUSD
  Expenses:SellingGeneralAdministrative           454.9 MUSD
  Expenses:ResearchAndDevelopment                 408.3 MUSD
  Income:OtherNet                                 -75.8 MUSD
  Expenses:IncomeTax                               144.0 MUSD
  Expenses:OtherNet                                  1.6 MUSD
  Equity:Adjustments                               522.8 MUSD

The balance-sheet number that tells the narrative is the cash pile — or rather, where it went:

Cash and investments fell $2.23 billion in nine months — $1.83 billion of it in Q3 alone — "primarily driven by cash used for repurchases of common stock," in the release's words. The Q3 buyback was 7.8 million shares for $2.94 billion, more than five times the quarter's GAAP net income. Meanwhile liabilities jumped 28%, and the shape is visible in the ledger: "accounts payable and other liabilities" rose $643 million year to date, which is where the $450 million settlement payable sits before it is paid. Intuitive carries no debt at all — the only leverage on this balance sheet is a lawsuit.

The Multi-Year Arc​

Three years of acceleration: revenue growth stepping from 17% to 20% to 22%, operating margin (cleaned) marching from 25% toward 34%, and an installed base compounding at 12% a year — each system a future stream of instruments, accessories and service contracts. FY2025 crossed $10 billion of revenue with a 28% net margin, a combination almost no hardware company achieves, because Intuitive is barely a hardware company: 59% of revenue is consumables pulled through by procedures. The Q3 GAAP margins look like a break in the trend; ex-settlement, they are its continuation.

The Verdict: Bull vs. Bear​

Bull Case

• Procedures grew 15% and instruments revenue 18% — the flywheel (installed base → procedures → consumables) is intact and accelerating with revenue.
• The da Vinci 5 cycle is real: 315 placements (+31%), now 58% of the mix, with a higher lease installed base smoothing future revenue.
• Gross margin expanded 200 bps to 68.4% despite tariff drag — mix and scale are more than offsetting Mexico/Germany exposure.
• Cleaned earnings of ~$845M (+~20%) plus a $2.94B buyback on a zero-debt balance sheet: a compounder returning cash while it grows.
• Full-year procedure guidance of 14–15% growth keeps the consumable stream compounding into 2027.

Bear Case

• A $450 million antitrust settlement "without any admission of liability" still costs $450 million — and includes injunctive relief plus the risk a court rejects it or class members object.
• Management narrowed the procedure outlook and the stock fell 7%: expectations, not results, are the binding constraint at this multiple.
• China is capping robotic-surgery prices and domestic competitors are entering those tenders — the 10-K's pricing risk with no release commentary to offset it.
• The GAAP/non-GAAP gap is structural, not just this quarter: $213M of quarterly SBC is permanent dilution dressed as an add-back.
• Tariffs are a 0.9-point gross-margin headwind with "material" further risk if more are implemented — and the IEEPA refunds flattering 2026 are one-time.

Our Take

Buy the flywheel, discount the print. The business did exactly what a bull wants — 15% procedure growth, 30% systems growth, expanding gross margins, cash returned — and the GAAP miss is a settlement check, not an operating decay. But the 7% selloff is rational too: when a quarter this good still sells off on a narrowed outlook sentence, the shares are priced for the top of every range. The ledger says the company is worth more than $523 million a quarter; the market is arguing about whether it is worth its multiple. On the numbers alone, we side with the flywheel.